Citadel Advisors
ANTX icon

Citadel Advisors’s AN2 Therapeutics ANTX Stock Holding History

Citadel Advisors’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.61M Buy
951,997
+796,758
+513% +$3.43M ﹤0.01% 4870
2026
Q1 		$531K Buy
155,239
+39,703
+34% +$81.9K ﹤0.01% 9154
2025
Q4 		$132K Buy
115,536
+92,523
+402% +$108K ﹤0.01% 11427
2025
Q3 		$29.2K Buy
23,013
+10,516
+84% +$12K ﹤0.01% 12405
2025
Q2 		$13.2K Buy
+12,497
New +$14.9K ﹤0.01% 12173
2025
Q1 		– Sell
-67,994
Closed -$93.8K – 14412
2024
Q4 		$93.8K Buy
+67,994
New +$82.5K ﹤0.01% 11569
2024
Q3 		– Sell
-1,553,829
Closed -$3.34M – 14177
2024
Q2 		$3.34M Sell
1,553,829
-2,725
-0.2% -$6.49K ﹤0.01% 4390
2024
Q1 		$5.06M Sell
1,556,554
-288
-0% -$3.13K ﹤0.01% 3938
2023
Q4 		$31.9M Buy
1,556,842
+290
+0% +$4.85K 0.01% 1567
2023
Q3 		$25M Buy
1,556,552
+219,569
+16% +$2.49M 0.01% 1640
2023
Q2 		$11.4M Sell
1,336,983
-176
-0% -$1.26K ﹤0.01% 2511
2023
Q1 		$13.2M Buy
1,337,159
+176
+0% +$1.96K ﹤0.01% 2443
2022
Q4 		$12.7M Hold
1,336,983
– – ﹤0.01% 2489
2022
Q3 		$23.2M Buy
1,336,983
+3,167
+0.2% +$36.9K 0.01% 1730
2022
Q2 		$9.92M Sell
1,333,816
-86,035
-6% -$1.14M ﹤0.01% 2698
2022
Q1 		$20.6M Buy
+1,419,851
New +$21.5M ﹤0.01% 1955

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors's ANTX Position: Q2 2026 in Review

Citadel Advisors increased its AN2 Therapeutics (ANTX) stake by 513% in Q2 2026, buying an estimated $3.43M and bringing the position to 951,997 shares worth $4.61M. The position accounts for ﹤0.01% of the portfolio, ranked #4870.

Citadel Advisors first reported a position in ANTX in Q1 2022 and has held it in 16 quarters since. The position peaked at $31.9M in Q4 2023. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Citadel Advisors held 951,997 shares of AN2 Therapeutics worth $4.61M as of Q2 2026.
  • Citadel Advisors bought 796,758 AN2 Therapeutics shares in Q2 2026, an estimated $3.43M.
  • AN2 Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4870 holding.
  • Citadel Advisors first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • Citadel Advisors's AN2 Therapeutics position peaked at $31.9M in Q4 2023.
  • 59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.